Israel Englander Aim Immuno Tech Inc. Transaction History

Millennium Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.31 - $0.6 $3,459 - $6,696	-11,161 Reduced 38.02%	18,191 $6,000
Q3 2022 Nov 14, 2022	BUY	$0.57 - $0.81 $16,730 - $23,775	29,352 New	29,352 $17,000
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.27 $10,165 - $16,551	-13,033 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.67 - $1.18 $42 - $74	63 Added 0.49%	13,033 $14,000
Q4 2021 Feb 14, 2022	SELL	$0.92 - $1.96 $38,093 - $81,155	-41,406 Reduced 76.15%	12,970 $12,000
Q3 2021 Nov 15, 2021	BUY	$1.91 - $2.17 $103,858 - $117,995	54,376 New	54,376 $110,000
Q4 2020 Feb 16, 2021	SELL	$1.68 - $2.45 $29,761 - $43,401	-17,715 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.77 - $3.88 $31,355 - $68,734	17,715 New	17,715 $38,000
Q2 2020 Aug 14, 2020	SELL	$1.9 - $2.94 $369,367 - $571,547	-194,404 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.56 - $6.1 $108,866 - $1.19 Million	194,404 New	194,404 $498,000

9.01M

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $10.1M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.